Human Papillomavirus (HPV) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033 thelansis.com

Human papillomavirus (HPV) constitutes a diverse group of over 100 viruses primarily transmitted through sexual contact. Individuals with persistent HPV infections and those engaging in multiple sexual partnerships face an elevated risk of acquiring various HPV subtypes. The current categorization of HPV infections encompasses non-genital (cutaneous), mucosal or anogenital, and epidermodysplasia verruciformis (EV). As the majority of HPV infections are asymptomatic, a significant number of individuals remain unaware of their infection. Predominantly affecting young people in their teens and early twenties, most new infections resolve spontaneously, with an average clearance time of up to two years. However, unresolved infections may progress to cancer, with HPV being a leading cause of cervical cancer and a substantial contributor to vulvar, vaginal, penile, anal, and oropharyngeal cancers, particularly in males. Symptomless infections are common, though certain HPV types can manifest as genital warts, presenting as singular or clustered bumps in the genital region. While the prognosis following an HPV infection is generally favorable, recurrence is frequent. Despite the availability of various wart treatments, efficacy remains limited, necessitating repeated interventions. HPV infections also pose the risk of vulvar intraepithelial dysplasia, cervical dysplasia, and cervical cancer. Some women persist in being at heightened risk for developing vaginal and anal cancer, particularly those with compromised immune systems. Furthermore, individuals diagnosed with HPV face a 5-20% risk of concomitant sexually transmitted diseases such as gonorrhea and chlamydia. In December 2014, the United States Food and Drug Administration (FDA) approved Gardasil 9 (Human Papillomavirus 9-valent Vaccine, Recombinant), which is designed to prevent diseases caused by nine specific types of HPV.

Thelansis’s “Human Papillomavirus (HPV) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Human Papillomavirus (HPV) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Human Papillomavirus (HPV) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Human Papillomavirus (HPV) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Human Papillomavirus (HPV) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033